Changes in plan coverage/plan designPatients may experience a change in cost share, stricter prior authorization requirements or even lose coverage.
doi:10.1200/JCO.2026.44.19_suppl.138 Jajja S, Thukral J, Abdalla A, et al
Moving beyond the traditional fragmented perspectives that have limited our understanding and management of the disease, our analysis of current information on ME/CFS represents a significant paradigm shift by synthesising the diseases multifactorial origins into a cohesive model
This new study adds to a growing body of evidence that GLP-1 medicines may play a role in lowering dementia risk. After applying matching methods to control for confounding factors, the study included over 174,000 patients, evenly divided between the two treatment groups
Food Chem 194, 843848 (2016)